Press Releases

InVivo Therapeutics Announces Indiana’s Goodman Campbell Brain and Spine as New Site for Neuro-Spinal Scaffold Clinical Trial

Published: May 19, 2015

CAMBRIDGE, Mass. (May 19, 2015) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that Goodman Campbell Brain and Spine in Indianapolis, IN has been added as a clinical site in the company’s ongoing pilot study of its investigational Neuro-Spinal Scaffold in patients with acute spinal cord injury (SCI). Goodman Campbell Brain and Spine is the merger of two highly-respected institutions: Indianapolis Neurosurgical Group and Indiana University Department of Neurological Surgery, providing a complement of exceptional medical-practice expertise and world-renowned academic research. Procedures will be performed at Indiana University Health Methodist Hospital. Eric Horn, M.D., Ph.D., Assistant Professor of Neurological Surgery […]

View Article
InVivo Therapeutics Reports Update of First Two Spinal Cord Injury Patients Implanted with Neuro-Spinal Scaffold

Published: May 14, 2015

CAMBRIDGE, Mass. (May 14, 2015) – InVivo Therapeutics Holdings Corp. (NVIV) today announced a six-month post-implant update for the first study patient and a three-month post-implant update for the second study patient in the company’s ongoing pilot trial of its investigational Neuro-Spinal Scaffold in patients with acute spinal cord injury. The Neuro-Spinal Scaffold was implanted in the first patient in October 2014 at the Barrow Neurological Institute, Phoenix, AZ and in the second patient in January 2015 at the Carolinas Medical Center, Charlotte, NC. From the three-month assessment to the six-month assessment, the first patient has demonstrated continued improvement in […]

View Article
InVivo Therapeutics Reports 2015 First Quarter Financial Results and Business Update

Published: May 7, 2015

CAMBRIDGE, Mass. (May 7, 2015) – InVivo Therapeutics Holdings Corp. (NVIV) today reported financial results for the quarter ended March 31, 2015. Mark Perrin, the CEO and Chairman of InVivo, said, “We continued to make great progress in the first quarter.  We reported very encouraging results from the first patient in the ongoing pilot study of our investigational Neuro-Spinal Scaffold. We were able to quickly enroll the second patient and later reopened the study for concurrent enrollment of the final three patients. We also significantly improved our cash position through a registered direct offering in January and the proceeds from […]

View Article
InVivo Therapeutics to Exhibit at the 83rd AANS Annual Scientific Meeting

Published: May 1, 2015

- Preclinical and Clinical Abstracts to be Presented at Scientific Sessions – CAMBRIDGE, Mass. (May 1, 2015) – InVivo Therapeutics Holdings Corp. (NVIV) today announced the company will be exhibiting at the 83rd American Association of Neurological Surgeons (AANS) Annual Scientific Meeting to be held in Washington, D.C. May 2-6, 2015. As the premier neurological society, the AANS expects over 3,000 attendees at this year’s meeting. The InVivo exhibit will focus on increasing awareness about the ongoing Investigational Device Exemption (IDE) pilot trial of its Neuro-Spinal Scaffold in subjects with acute spinal cord injury. Members of InVivo’s management will be […]

View Article
InVivo Therapeutics Announces Uplisting to Nasdaq

Published: April 16, 2015

CAMBRIDGE, Mass. (April 16, 2015) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that its common stock has been approved to begin trading on The Nasdaq Capital Market. The company’s common stock will begin trading under the symbol “NVIV” at the opening of trading on Friday, April 17, 2015. “We are pleased to reach this important corporate milestone. InVivo has made significant progress spanning all areas of the organization over the last year and uplisting to Nasdaq will allow us to communicate this progress with a broader audience. We are now better positioned to enhance stock liquidity and attract institutional investors, […]

View Article
InVivo Therapeutics Announces Implementation of Reverse Stock Split in Preparation for Planned Uplisting to NASDAQ

Published: April 8, 2015

CAMBRIDGE, Mass. (April 8, 2015) – InVivo Therapeutics Holdings Corp. (NVIV) today announced the  implementation of its previously disclosed 1-for-4 reverse stock split as of today, April 8, 2015, a key step in preparation for its planned uplisting to the NASDAQ Capital Market. “We are pleased to have completed the reverse stock split in preparation for uplisting, which we believe will result in better liquidity and attract additional investors to our company. Although we cannot make any assurances, we are hopeful NASDAQ will accept our listing application and that we will begin trading on the exchange in the imminent future,” said […]

View Article
InVivo Therapeutics Announces New Clinical Trial Site for Neuro-Spinal Scaffold

Published: April 1, 2015

CAMBRIDGE, Mass. (April 1, 2015) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that UC Davis Medical Center in Sacramento, CA has been added as a clinical site in the company’s ongoing IDE pilot study of its Neuro-Spinal Scaffold in patients with acute spinal cord injury (SCI). The medical center serves a 65,000 square-mile territory that includes 33 counties and 6 million residents across northern and central California. Mark Perrin, InVivo’s CEO and Chairman, said, “I am pleased with this newest addition to InVivo’s ongoing clinical study of our Neuro-Spinal Scaffold. We now have ten clinical sites open to enroll the […]

View Article
InVivo Therapeutics Announces University of Kansas Medical Center as New Site for Neuro-Spinal Scaffold Clinical Trial

Published: March 30, 2015

CAMBRIDGE, Mass. (March 30, 2015) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that the University of Kansas Medical Center in Kansas City, KS has been added as a clinical site in the company’s ongoing Investigational Device Exemption (IDE) pilot study of its Neuro-Spinal Scaffold in patients with acute spinal cord injury (SCI). Paul Arnold, MD, Professor of Neurosurgery and Vice Chair of Research, has been named Principal Investigator at the site. “We look forward to participating in this exciting pilot study of an innovative device that is targeted at addressing the huge unmet medical need in the treatment of acute […]

View Article
InVivo Therapeutics Exhibiting at 66th Southern Neurosurgical Society Annual Meeting

Published: March 27, 2015

CAMBRIDGE, Mass. (March 27, 2015) – InVivo Therapeutics Holdings Corp. (NVIV) today announced the company is exhibiting at the 66th Southern Neurosurgical Society (SNS) Annual Meeting being held in Naples, Florida on March 25-28, 2015. Tom Ulich, MD, InVivo’s Chief Scientific Officer, and Lorianne Masuoka, MD, InVivo’s Chief Medical Officer, are presenting intraoperative videos from the company’s ongoing Investigational Device Exemption (IDE) pilot study, which has enrolled two subjects thus far.  The videos provide an update to the neurosurgical community on the company’s investigational Neuro-Spinal Scaffold novel implantation techniques, which until InVivo’s pilot study, had never been performed in patients with […]

View Article
InVivo Therapeutics Announces Reopening of Enrollment for Subjects Three through Five for Anticipated Completion of Ongoing Pilot Trial

Published: March 26, 2015

CAMBRIDGE, Mass. (March 26, 2015) – InVivo Therapeutics Holdings Corp. (NVIV) today announced the reopening of subject enrollment for the company’s ongoing Investigational Device Exemption (IDE) pilot study of its investigational Neuro-Spinal Scaffold in patients with acute spinal cord injury. Barring significant safety issues, the final three subjects of this pilot trial will be enrolled concurrently and without mandatory safety hold between enrollment of each subject. To date, there have been no reported serious safety events related to the Neuro-Spinal Scaffold or the procedure to implant the Neuro-Spinal Scaffold with the study’s first and second subjects, and InVivo has been approved […]

View Article

The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on the InVivo website for historical purposes only. InVivo assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.